Extended-release dalfampridine in the management of multiple-sclerosis-related walking impairment

Therapeutic Advances in Neurological Disorders

Volumn 5, Issue 4, 2012, Pages 199-204

  Hersh, Carrie ^a   Rae Grant, Alex ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

12 Item Multiple Sclerosis Walking Scale; ambulation; extended release dalfampridine; Lower Extremity Manual Muscle Test; multiple sclerosis; potassium channel blocker; Timed 25 Foot Walk test

Indexed keywords

4 AMINOPYRIDINE; PLACEBO;

ANKLE FRACTURE; ANXIETY DISORDER; ASTHENIA; DIZZINESS; DRUG INDUCED HEADACHE; DRUG OVERDOSE; DRUG RELEASE; DRUG RESPONSE; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; FALLING; HUMAN; INSOMNIA; MULTIPLE SCLEROSIS; NAUSEA; PARESTHESIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SEPSIS; SIDE EFFECT; TONIC CLONIC SEIZURE; TREMOR; URINARY TRACT INFECTION; WALKING; WALKING DIFFICULTY;

EID: 84863567452     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285612447091     Document Type: Review

References (34)

1. Acorda Therapeutics, Inc. (2010) Ampyra (package insert). New York: Acorda Therapeutics, Inc.
2. Alonso A. Hernan M.A. (2008) Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 71: 129–134.
3. Bethoux F. Bennett S. (2011) Evaluating walking in patients with multiple sclerosis: which assessment tools are useful in clinical practice? Int J MS Care 13: 4–14.
4. Bever C.T. Jr Judge S. IV (2009) Sustained-release fampridine for multiple sclerosis. Exp Opin Investig Drugs 18: 1013–1024.
5. Bever C.T. Young D. Anderson P.A. Krumholz A. Conway K. Leslie J. et al. (1994) The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double blind, concentration controlled crossover trial. Neurology 44: 1054–1059.
6. Blight A.R. Henney H.R. (2009) Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labled fampridine (4-aminopyridine) in healthy volunteers. Clin Ther 31: 328–335.
7. Coleman C.I. Sobieraj D.M. Marinucci L.N. (2012) Minimally important clinical difference of the Timed 25-Foot Walk Test: results from a randomized controlled trial in patients with multiple sclerosis. Curr Med Res Opin 28: 1–8.
8. Confavreux C. Compston A. (2005) The natural history of multiple sclerosis. In: Ed. Compston A. (ed) McAlpine's Multiple Sclerosis. 4th edition. Philadelphia, PA: Churchill Livingstone, pp. 183–269.
9. de Grazio J.W. Besser J.F. de Cino T.J. Guarino J.L. Starr R.I. (1971) Use of 4-aminopyridine to protect ripening corn from blackbirds. J Wildl Mgmt 35: 565–569.
10. Dunn J. Blight A. (2011) Extended-release dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis. Curr Med Res Opin 27: 1415–1423.
11. Espejo C. Montalban X. (2012) Dalfampridine in multiple sclerosis: from symptomatic treatment to immunomoduluation. Clin Immunol 142: 84–92.
12. Evenhuis J. Agoston S. Salt P.J. Chir B. de Lange A.R. Wouthuyzen W. et al. (1981) Pharmacokinetics of 4-aminopyridine in human volunteers: a preliminary study using a new GLC method for its estimation. Br J Anesth 53: 567–570.
13. Frohman E. Racke M. Raine C. (2006) Multiple sclerosis: the plaque and its pathogenesis. N Engl J Med 354: 942–955.
14. Goodman A.D. Brown T.R. Cohen J.A. Krupp L.B. Schapiro R. Schwid S.R. et al. (2008) Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 71: 1134–1141.
15. Goodman A.D. Brown T.R. Edwards K.R. Krupp L.B. Schapiro R.T. Cohen R. et al. (2010) A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 68: 494–502.
16. Goodman A.D. Brown T.R. Krupp L.B. Schapiro R.T. Schwid S.T. Cohen R. et al. (2009) Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 373: 732–738.
17. Goodman A.D. Cohen J.A. Cross A. Vollmer T. Rizzo M. Cohen R. et al. (2007) Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose ranging study. Mult Scler 13: 357–368.
18. Hayes K.C. Katz M.A. Devane J.G. Hsieh J.T.C. Wolfe D.L. Potter P.J. et al. (2003) Pharmacokinetics of an immediate-release oral formulation of fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury. J Clin Pharmacol 31: 379–385.
19. Heesen C. Böhm J. Reich C. Kasper J. Goebel M. Gold S.M. (2008) Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable. Mult Scler 14: 988–991.
20. Jones H.E. Heron J.R. Foster D.H. Snelgar R.S. Mason R.J. (1983) Effects of 4-aminopyridine in patients with multiple sclerosis. J Neurol Sci 60: 353–362.
21. Judge S. IV. Bever C.T. (2006) Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharm Ther 111: 224–259.
22. Lemeignan M. Lechat P. (1967) Sur l'action anticurare des aminopyridines [On the anticurare action of aminopyridines]. C R Acad Sci Paris Serie D 264: 169–172.
23. Martin C.L. Phillips B.A. Kilpatrick T.J. Butzkueven H. Tubridy N. McDonald E. et al. (2006) Gait and balance impairment in early multiple sclerosis in the absence of clinical disability. Mult Scler 12: 620–628.
24. Polman C.H. Bertelsmann F.W. van Loenen A.C. Koetseier J.C. (1994) 4-Aminopyridine in the treatment of patients with multiple sclerosis: long-term efficacy and safety. Arch Neurol 51: 292–296.
25. Rasband M.N. (2005). Potassium channel organization of myelinated and demyelinated axons. In: Ed. Waxman S.G. (ed) Multiple Sclerosis as a Neuronal Disease. Amsterdam: Elsevier Academic Press, pp. 57–67.
26. Sherratt R.M. Bostock H. Sears T.A. (1980) Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres. Nature 283: 570–572.
27. Snappin S.M. Jiang Q. (2007) Responder analyses and the assessment of a clinically relevant treatment effect. Trials 8: 31.
28. Swingler R.J. Compston D.A. (1992) The morbidity of multiple sclerosis. Q J Med 83: 325–337.
29. Thomsen R.H. Wilson D.F. (1983) Effects of 4-aminopyridine and 3,4-diaminopyridine on transmitter release at the neuromuscular junction. J Pharmacol Exp Ther 227: 260–265.
30. Tremlett H. Paty D. Devonshire V. (2006) Disability progression in multiple sclerosis is slower than previously reported. Neurology 66: 172–177.
31. Uges D.R.A. Sohn Y.J. Greijdanus B. Scat A.H.J. Agoston S. (1982) 4-Aminopyridine kinetics. Clin Pharmacol Ther 31: 587–593.
32. van Diemen H.A.M. Polman C.H. Koetsier J.C. van Loenen A.C. Nauta J.J.P. Bertelsmann F.W. (1993) 4-Aminopyridine in patients with multiple sclerosis: dosage and serum level related to efficacy and safety. Clin Neuropharmacol 16: 195–204.
33. Waxman S.G. (1982) Membranes, myelin, and the pathophysiology of multiple sclerosis. N Engl J Med 306: 1529–1533.
34. Zwibel H.L. (2009) Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis. Adv Ther 26: 1043–1057.